This is a procurement-oriented overview for distributors, hospitals, and clinics evaluating oncology ablation devices. Beyond needle-based approaches, focused laser energy delivered through endoscopic instruments can be used trans-urethrally to vaporize or coagulate bladder tumors and to treat benign prostatic hyperplasia (BPH) with the aim of limiting bleeding. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Percutaneous Tumor Ablation
Thermal methods dominate the field: radiofrequency ablation (RFA) and microwave ablation (MWA) heat tissue to cytotoxic temperatures, while cryoablation instead freezes the target to lethal cold. Because ablation is a local therapy, tumor size, number, location relative to vessels and organs, and overall clinical status all influence whether it is appropriate, as determined by a multidisciplinary clinician team. Beyond needle-based approaches, focused laser energy delivered through endoscopic instruments can be used trans-urethrally to vaporize or coagulate bladder tumors and to treat benign prostatic hyperplasia (BPH) with the aim of limiting bleeding.
Regulatory Status and Manufacturing
INVAMED's ablation portfolio spans several radiofrequency platforms, including the Peta RFA System for soft-tissue, liver, and nerve applications and the multi-application ThermoEdge RFA Platform, as well as the Fusion Intraosseous RFA System for spinal tumors. For intravesical therapy, the HyperTiss Intracavitary Hypothermia Set is positioned for adjunctive use alongside intravesical chemotherapy in bladder cancer. Generator specifications, applicator and antenna options, and compatible accessories are provided in product documentation, and buyers should request the relevant IFU for each variant. Procurement teams should confirm local regulatory registration and approved indications, which vary by market and by device configuration.
Portfolio and Sizing
Within this category, INVAMED lists devices such as HyperTiss Intracavitary Hypothermia Set for Bladder Cancer Treatment, Fusion Intraosseous Radiofrequency Ablation System for Spinal Tumors, Peta Radiofrequency Ablation, ThermoEdge RFA Platform. Size ranges, materials, and configurations are detailed in product documentation and the applicable IFU.
Key Considerations
- Tumor size, number, and proximity to vessels and adjacent organs are central factors in deciding whether ablation is appropriate and which modality to use.
- For lesions near large vessels, the heat-sink effect can influence the completeness of heat-based ablation and is factored into planning.
- Image guidance with ultrasound, CT, or other modalities supports accurate applicator placement and monitoring of the treatment zone.
Frequently Asked Questions
Is the HyperTiss set an ablation device?
INVAMED describes HyperTiss as an intracavitary (intravesical) temperature-therapy set intended for adjunctive use with intravesical chemotherapy in bladder cancer, rather than as a standalone tumor ablation device.
What determines the ablation zone size?
Published sources note that factors such as generator power, applicator design, application time, and local blood flow influence the ablation zone, and settings are selected by the treating physician.
What radiofrequency ablation systems does INVAMED offer?
INVAMED offers the Peta RFA System, positioned for soft-tissue, liver, and nerve applications, the multi-application ThermoEdge RFA Platform, and the Fusion Intraosseous RFA System for spinal tumors.
About INVAMED
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Clinical and Technical Context
Tumor size, number, and proximity to vessels and adjacent organs are central factors in deciding whether ablation is appropriate and which modality to use. Wavelength, fiber type, and power settings influence the balance between vaporization and coagulation, and are selected according to the instrument system and clinical goal. This is an endoscopic energy technique whose indication and parameters are established by the treating urologist rather than by any general rule. For lesions near large vessels, the heat-sink effect can influence the completeness of heat-based ablation and is factored into planning.
Related on INVAMED
- Oncology Ablation — product category
- Understanding Radiofrequency Ablation (RFA) for Liver Tumors
- Is ablation as good as surgery for liver cancer?
- How long is recovery after tumor ablation?
Important Disclaimer
This article is intended for general educational and technical information about medical device technologies. It is not medical advice, a diagnosis, or a treatment recommendation, and it does not replace consultation with a qualified healthcare professional. Any decision about diagnosis or treatment should be made by a licensed clinician based on an individual assessment. INVAMED devices are intended for use by trained healthcare professionals in accordance with the applicable Instructions for Use (IFU) and local regulatory approvals. Product availability and indications vary by country.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.